Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea

NCT01778023 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01778023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01778023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
January 17, 2013
Completion date
December 17, 2014
Enrollment
54 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

growth disorder, idiopathic short stature